Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is a Phase I/IIa, multi-center, open-label study of BR790 in combination with
Tislelizumab with a dose escalation part followed by a dose expansion part in adult subjects
with advanced solid tumors.
These treatment to characterize the safety, tolerability, PK, PD and preliminary antitumor
activity.
The study treatment will be administered until the subject experiences unacceptable toxicity,
progressive disease, and/or has treatment discontinued at the discretion of the Investigator
or the subject, or due to withdrawal of consent.